Opening Targeting Apoptosis in Leukemia: Lessons and Challenges (Yale Cancer Center Grand Rounds)
Targeting Apoptosis in Leukemia: Lessons and Challenges (Yale Cancer Center Grand Rounds)
- Length
- 1 h 3 min
- Level
- Research
- Recorded
- Yale University2024
Chapter 1 of 10: Before the lecture
Follows venetoclax in AML from weak single-agent trials through drug combinations to BCL-XL degraders.
Acute myeloid leukemia evades cell death through BCL2 family proteins, the target of venetoclax. At Yale Cancer Center Grand Rounds, Konopleva traces the drug from the ABT-737 work to preclinical evidence of BCL2 upregulation in AML and disappointing single-agent trials. Combinations with hypomethylating agents improved survival in older unfit patients, while MAPK activation, RAS mutations and FLT3-ITD drive resistance. Later sections weigh CD123 antibody-drug conjugates, metronomic decitabine for TP53 loss, and venetoclax with chemotherapy. The talk closes on BCL-XL: PROTAC degraders that spare platelets, and a specific BCL-XL dependency in acute erythroid leukemia.
Acute myeloid leukemia evades cell death through BCL2 family proteins, the target of venetoclax. At Yale Cancer Center Grand Rounds, Konopleva traces the drug from the ABT-737 work to preclinical evidence of BCL2 upregulation in AML and disappointing single-agent trials. Combinations with hypomethylating agents improved survival in older unfit patients, while MAPK activation, RAS mutations and FLT3-ITD drive resistance. Later sections weigh CD123 antibody-drug conjugates, metronomic decitabine for TP53 loss, and venetoclax with chemotherapy. The talk closes on BCL-XL: PROTAC degraders that spare platelets, and a specific BCL-XL dependency in acute erythroid leukemia.
An inhibitor of Bcl-2 family proteins induces regression of solid tumours
Souers et al (2013) Nature Medicine
Pan et al., Cancer Discovery, 2014
Andrew Way's publication
Di Nordo et al, ASH 2015
Lin et al, ASCO 2016

This lecture
Talk 20 of 26 of Yale Cancer Center Grand Rounds.
Choose a node to see how it connects to this lecture. What comes before is on the leftat the top. What comes after is on the rightat the bottom. The ring is what it teaches. People and places are above. Other lectures and books are below.
Press a chosen node again to open it.
Your comment is kept while you sign up.Sign in
DiNardo et al, N Engl J Med. 2020;383:617-629
Ong et al, Cancer Drug Resistance 2022
Zhang Q. Signal Transduct Target Ther. 7(1):51, 2022
Genomic subsets analysis from Viale A study
FLT3 Inhibitors and Venetoclax: Synergy and Priming
Venetoclax + Gilteritinib for R/R FLT3-Mutated AML
Novel Triplets (Azacitidine, Venetoclax, and Gilteritinib) Show Promising Activity in Newly Diagnosed AML
Allosteric B-Raf/FLT3 inhibitor: Pre-clinical Efficacy in VEN-R AML
Venetoclax in Novel Combinations
ASH 2023 presentation and JCO paper
Andrew Way paper
Clin Cancer Res. 2023; 29(15):2774-2780
Nat. Chem. Biol. 2012
Blood 2021
J Clin Oncol. 2020; 38:3506-3517
Lancet Haematol. 2022; 9:e348-358
J Clin Oncol. 2021;39:2768-2778
EHA 2023 Abstract P488
Cancer Res 2023
Nat Med 2019
Haematologica 2023
JCO 2023; 41($16_{\mathrm{suppl}}$):e19031
Blood 2022
Crispino 2019